Assay Development, Licensing and Trials

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Assay Development

Licensing

Trials

The hidden risks of over-reliance on healthy donor material

Drug Target Review

OCTOBER 10, 2024

What are the risks of over-reliance on healthy donor material in early-stage research, and how can decision-makers ensure a balanced integration of diseased material to avoid potential gaps when transitioning to clinical trials? Healthy cells may also serve as a valuable control in experiments.

Therapies

Therapies Immune Response Clinical Trials Disease

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

The Pharma Data

JANUARY 27, 2021

We look forward to working with Eurofins Discovery to bring this treatment to patients as quickly as possible as we prepare for our IND and trials,” said BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian.

FDA

FDA Synthetic Chemistry Assay Development Treatment

Drug Discovery Digest

The hidden risks of over-reliance on healthy donor material

BetterLife Engages Eurofins Discovery for its Next Generation Psychedelics 2-bromo-LSD FDA IND-enabling Pharmacology Studies

Stay Connected